Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

Albert Oriol, Pilar Giraldo, Ioannis Kotsianidis, Catherine Couturier, Robert Olie, Ralf Angermund, Alessandro Corso

Research output: Contribution to journalArticle

Abstract

Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalHematology
Volume20
Issue number7
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Retreatment
Multiple Myeloma
Retrospective Studies
Safety
Recurrence
Therapeutics
Observational Studies
Bortezomib

Keywords

  • Bortezomib
  • Efficacy
  • Multiple myeloma
  • Retreatment
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients : A retrospective study. / Oriol, Albert; Giraldo, Pilar; Kotsianidis, Ioannis; Couturier, Catherine; Olie, Robert; Angermund, Ralf; Corso, Alessandro.

In: Hematology, Vol. 20, No. 7, 01.08.2015, p. 405-409.

Research output: Contribution to journalArticle

Oriol, Albert ; Giraldo, Pilar ; Kotsianidis, Ioannis ; Couturier, Catherine ; Olie, Robert ; Angermund, Ralf ; Corso, Alessandro. / Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients : A retrospective study. In: Hematology. 2015 ; Vol. 20, No. 7. pp. 405-409.
@article{c6a509afcf0c438a8ca1caeb04d486c6,
title = "Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study",
abstract = "Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.",
keywords = "Bortezomib, Efficacy, Multiple myeloma, Retreatment, Safety",
author = "Albert Oriol and Pilar Giraldo and Ioannis Kotsianidis and Catherine Couturier and Robert Olie and Ralf Angermund and Alessandro Corso",
year = "2015",
month = "8",
day = "1",
doi = "10.1179/1607845414Y.0000000218",
language = "English",
volume = "20",
pages = "405--409",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients

T2 - A retrospective study

AU - Oriol, Albert

AU - Giraldo, Pilar

AU - Kotsianidis, Ioannis

AU - Couturier, Catherine

AU - Olie, Robert

AU - Angermund, Ralf

AU - Corso, Alessandro

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.

AB - Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.

KW - Bortezomib

KW - Efficacy

KW - Multiple myeloma

KW - Retreatment

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84939151815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939151815&partnerID=8YFLogxK

U2 - 10.1179/1607845414Y.0000000218

DO - 10.1179/1607845414Y.0000000218

M3 - Article

C2 - 25494809

AN - SCOPUS:84939151815

VL - 20

SP - 405

EP - 409

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 7

ER -